Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms, Squamous Cell × Cilengitide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Gliosarcoma 2 Glioblastoma 2 Recurrence 1 Oligodendroglioma 1 Neoplasms, Squamous Cell 1 Neoplasm Metastasis 1 Central Nervous System Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Cetuximab 3 temsirolimus 1 osimertinib 1 cobimetinib 1 Sorafenib 1 Nivolumab 1 Fluorouracil 1 Cisplatin 1 Cilengitide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00705016 2014-04-30

ADVANTAGE

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed

184 enrolled 20 charts

Neoplasm Metastasis, Recurrence, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡